Latest News

GSK’s COVID-related sales close to $2 billion, profit boost to wane in 2022

© Reuters. FILE PHOTO: A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

By Pushkala Aripaka and Ludwig Burger

(Reuters) – Britain’s GSK forecast growth in 2022 after racking up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, beating quarterly forecasts in its first earnings report since rejecting Unilever (LON:ULVR)’s bid for its consumer arm.

The results underscore a comeback for GSK in the race to help fight the COVID-19 pandemic after it failed to bring a vaccine to the market so far. The spin off of the consumer venture with Pfizer (NYSE:PFE) has also put the future in focus as boss Emma Walmsley faces pressure from activist investors.

“We have ended the year strongly, with another quarter of excellent performance … and we enter 2022 with good momentum,” Walmsley said. “This is going to be a landmark year for GSK.”

The drugmaker is pressing on with the spin off of its consumer arm, home to brands such as Sensodyne toothpaste and Advil painkiller, after turning down Unilever’s 50 billion pound buyout offer for the unit in December.

But some activist investors had called on GSK to give more consideration to a potential sale of the unit. They have also questioned the ability of top management to boost the success rate of drug development, where GSK has long lagged peers.

The company said sales in 2022, after the spin-off of its consumer arm, were expected to grow 5% to 7% and adjusted operating profit to grow 12% to 14%. That includes the boost from a settlement with Gilead (NASDAQ:GILD) but not sales of its COVID-19 products.

Analysts had forecast group earnings of 120.8 pence per share, or a rise of about 8% from 2021, on sales of 36.28 billion pounds.

The company said it expected pandemic-related sales in 2022 to be at similar levels to 2021 but said these would contribute less to profit at “New GSK” due to lower margins on its antibody treatment, knocking off profit by 5% to 7%.`

GSK shares were up 0.3% in early trade.


GSK’s Sotrovimab, developed with Vir Biotechnology, is one of the few COVID-19 treatments shown to have worked against the fast-spreading Omicron variant, spurring demand. It was amongst GSK’s top selling offerings in 2021.

GSK has secured orders for 1.7 million doses of Sotrovimab, including from the United States, Canada and the European Union.

Sales of sotrovimab, branded Xevudy, stood at 828 million pounds in the fourth quarter, up from 114 million in the third quarter and above market expectations of 774 million pounds.

Revenue from shingles vaccine Shingrix, a key earnings driver over past quarters, slipped 7% to 597 million pounds but still surpassed consensus of 548 million pounds.

Adjusted earnings for the group stood at 25.6 pence per share for the three months to Dec. 31, while turnover rose 13% to 9.53 billion pounds at constant currency rates, topping a consensus of 23.8 pence apiece on sales of 9.49 billion pounds.

GSK said it expected key trial results in 2022 on up to seven future growth drivers including a long awaited read-out on a vaccine for the elderly against the common respiratory syncytial virus before the end of June.

GSK Chief Scientific Officer Hal Barron, the driving force behind a drug development revamp, said last month he planned to leave in August to run a privately-owned biotech start-up.

($1 = 0.7378 pounds)

GSK sees sales growth in 2022 after quarterly beat, prepares for spin-off

Disclaimer:Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

UK pre-market stocks update – Barratt Developments, GSK, Dunelm, Smurfit Kappa

Previous article

European, U.S. regulators tell banks to prepare for Russian cyberattack threat

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News